Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development
Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, aci...
Gespeichert in:
Veröffentlicht in: | European journal of pharmaceutical sciences 2017-11, Vol.109, p.389-401 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 401 |
---|---|
container_issue | |
container_start_page | 389 |
container_title | European journal of pharmaceutical sciences |
container_volume | 109 |
creator | Stolarczyk, Elżbieta U. Rosa, Anna Kubiszewski, Marek Zagrodzka, Joanna Cybulski, Marcin Kaczmarek, Łukasz |
description | Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability.
[Display omitted] |
doi_str_mv | 10.1016/j.ejps.2017.08.033 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1935385074</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098717304906</els_id><sourcerecordid>1935385074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi0EoqHwBzggH7nsxvZ-2RIXFFGolFCpH2fLa48TR9n1Ynsr8mP6X3GawpGTpfEzj2bmRegjJSUltF3uS9hPsWSEdiXhJamqV2hBeScK0jHyGi2IYLwggncX6F2Me0JIyzvyFl0wztum5e0CPT1EwN7itAO8O047GFUCg9erYnO33NzhBHo3ul8zYDUa_HNzu7y-xXECnYKP2k9HbH147nYGxuSs0yo5P56c8BsGiEmNgGMKECM2sA3KnIEpeDPrlItzcOP22WHCvM3QIxz8NGTde_TGqkOEDy_vJXq4-na_-lGsb75fr76uC101bSpaW2shNLWqo1xwpSvb85bpmlcCFFhKtTU9442tedMBq0XPoIGKMdGL_F1dos9nbx4q7xqTHFzUcDjk2f0cJRVVU_GGdHVG2RnV-QAxgJVTcIMKR0mJPMUi9_IUizzFIgmXOZbc9OnFP_cDmH8tf3PIwJczAHnLRwdBRu1g1GBcyLeWxrv_-f8AaX-h4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1935385074</pqid></control><display><type>article</type><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</creator><creatorcontrib>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</creatorcontrib><description>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability.
[Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2017.08.033</identifier><identifier>PMID: 28865686</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Androstadienes - chemistry ; Androstadienes - radiation effects ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - radiation effects ; Aromatase Inhibitors - chemistry ; Aromatase Inhibitors - radiation effects ; Chromatography, Liquid ; Drug Contamination ; Drug Stability ; Exemestane ; Forced degradation ; Fragmentation pathway ; Hydrochloric Acid - chemistry ; Hydrogen Peroxide - chemistry ; Hydrogen-Ion Concentration ; Hydrolysis ; Impurity profile ; LC-MS/MS ; Magnetic Resonance Spectroscopy ; Oxidants - chemistry ; Oxidation-Reduction ; Photolysis ; Sodium Hydroxide - chemistry ; Spectrophotometry, Infrared ; Stability indicating method ; Tandem Mass Spectrometry ; Ultraviolet Rays</subject><ispartof>European journal of pharmaceutical sciences, 2017-11, Vol.109, p.389-401</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</citedby><cites>FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0928098717304906$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28865686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stolarczyk, Elżbieta U.</creatorcontrib><creatorcontrib>Rosa, Anna</creatorcontrib><creatorcontrib>Kubiszewski, Marek</creatorcontrib><creatorcontrib>Zagrodzka, Joanna</creatorcontrib><creatorcontrib>Cybulski, Marcin</creatorcontrib><creatorcontrib>Kaczmarek, Łukasz</creatorcontrib><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability.
[Display omitted]</description><subject>Androstadienes - chemistry</subject><subject>Androstadienes - radiation effects</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - radiation effects</subject><subject>Aromatase Inhibitors - chemistry</subject><subject>Aromatase Inhibitors - radiation effects</subject><subject>Chromatography, Liquid</subject><subject>Drug Contamination</subject><subject>Drug Stability</subject><subject>Exemestane</subject><subject>Forced degradation</subject><subject>Fragmentation pathway</subject><subject>Hydrochloric Acid - chemistry</subject><subject>Hydrogen Peroxide - chemistry</subject><subject>Hydrogen-Ion Concentration</subject><subject>Hydrolysis</subject><subject>Impurity profile</subject><subject>LC-MS/MS</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Oxidants - chemistry</subject><subject>Oxidation-Reduction</subject><subject>Photolysis</subject><subject>Sodium Hydroxide - chemistry</subject><subject>Spectrophotometry, Infrared</subject><subject>Stability indicating method</subject><subject>Tandem Mass Spectrometry</subject><subject>Ultraviolet Rays</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1vEzEQhi0EoqHwBzggH7nsxvZ-2RIXFFGolFCpH2fLa48TR9n1Ynsr8mP6X3GawpGTpfEzj2bmRegjJSUltF3uS9hPsWSEdiXhJamqV2hBeScK0jHyGi2IYLwggncX6F2Me0JIyzvyFl0wztum5e0CPT1EwN7itAO8O047GFUCg9erYnO33NzhBHo3ul8zYDUa_HNzu7y-xXECnYKP2k9HbH147nYGxuSs0yo5P56c8BsGiEmNgGMKECM2sA3KnIEpeDPrlItzcOP22WHCvM3QIxz8NGTde_TGqkOEDy_vJXq4-na_-lGsb75fr76uC101bSpaW2shNLWqo1xwpSvb85bpmlcCFFhKtTU9442tedMBq0XPoIGKMdGL_F1dos9nbx4q7xqTHFzUcDjk2f0cJRVVU_GGdHVG2RnV-QAxgJVTcIMKR0mJPMUi9_IUizzFIgmXOZbc9OnFP_cDmH8tf3PIwJczAHnLRwdBRu1g1GBcyLeWxrv_-f8AaX-h4Q</recordid><startdate>20171115</startdate><enddate>20171115</enddate><creator>Stolarczyk, Elżbieta U.</creator><creator>Rosa, Anna</creator><creator>Kubiszewski, Marek</creator><creator>Zagrodzka, Joanna</creator><creator>Cybulski, Marcin</creator><creator>Kaczmarek, Łukasz</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171115</creationdate><title>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</title><author>Stolarczyk, Elżbieta U. ; Rosa, Anna ; Kubiszewski, Marek ; Zagrodzka, Joanna ; Cybulski, Marcin ; Kaczmarek, Łukasz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-6f4c99c1fa71898ac3fb862c4839eaef11cfdb285f4857e249b2e5e3229b9ef13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Androstadienes - chemistry</topic><topic>Androstadienes - radiation effects</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - radiation effects</topic><topic>Aromatase Inhibitors - chemistry</topic><topic>Aromatase Inhibitors - radiation effects</topic><topic>Chromatography, Liquid</topic><topic>Drug Contamination</topic><topic>Drug Stability</topic><topic>Exemestane</topic><topic>Forced degradation</topic><topic>Fragmentation pathway</topic><topic>Hydrochloric Acid - chemistry</topic><topic>Hydrogen Peroxide - chemistry</topic><topic>Hydrogen-Ion Concentration</topic><topic>Hydrolysis</topic><topic>Impurity profile</topic><topic>LC-MS/MS</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Oxidants - chemistry</topic><topic>Oxidation-Reduction</topic><topic>Photolysis</topic><topic>Sodium Hydroxide - chemistry</topic><topic>Spectrophotometry, Infrared</topic><topic>Stability indicating method</topic><topic>Tandem Mass Spectrometry</topic><topic>Ultraviolet Rays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stolarczyk, Elżbieta U.</creatorcontrib><creatorcontrib>Rosa, Anna</creatorcontrib><creatorcontrib>Kubiszewski, Marek</creatorcontrib><creatorcontrib>Zagrodzka, Joanna</creatorcontrib><creatorcontrib>Cybulski, Marcin</creatorcontrib><creatorcontrib>Kaczmarek, Łukasz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stolarczyk, Elżbieta U.</au><au>Rosa, Anna</au><au>Kubiszewski, Marek</au><au>Zagrodzka, Joanna</au><au>Cybulski, Marcin</au><au>Kaczmarek, Łukasz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2017-11-15</date><risdate>2017</risdate><volume>109</volume><spage>389</spage><epage>401</epage><pages>389-401</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) active pharmaceutical ingredient (EE-3) was subjected to thermal, photolytic, oxidative, acidic and base stress conditions prescribed by the ICH (International Conference on Harmonization) guideline Q1A(R2). EE-3 was found to degrade in base, acidic and oxidative conditions. Eleven new degradation products of EE-3 were characterized by the LC-MS/MS technique. One of these impurities was isolated and identified by the LC-MS/MS, NMR and IR techniques. The LC-MS/MS studies were carried out to establish fragmentation pathways of EE-3 and its new impurity. Based on the results obtained from different spectroscopic studies, this impurity was characterized as 3-hydroxy-1,6-dimethyl-oestratetraen-(1, 3, 5(10), 6)-17-one (EE-3Z). The degradation pathway of EE-3 leading to the generation of eleven products was proposed and this has not been reported so far. The separation of EE-3 from its impurities (process-related and degradants) was achieved using a Gemini C18 column (150mm×4.6mm×3μm) with gradient elution. The degradation products were well resolved from the main peak and its impurities, thus proving the method's stability and indicating power of the method. The method was validated according to the ICH guidelines for parameters such as specificity, limit of detection, limit of quantitation, precision, linearity, accuracy, robustness and system suitability.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28865686</pmid><doi>10.1016/j.ejps.2017.08.033</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0928-0987 |
ispartof | European journal of pharmaceutical sciences, 2017-11, Vol.109, p.389-401 |
issn | 0928-0987 1879-0720 |
language | eng |
recordid | cdi_proquest_miscellaneous_1935385074 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Androstadienes - chemistry Androstadienes - radiation effects Antineoplastic Agents - chemistry Antineoplastic Agents - radiation effects Aromatase Inhibitors - chemistry Aromatase Inhibitors - radiation effects Chromatography, Liquid Drug Contamination Drug Stability Exemestane Forced degradation Fragmentation pathway Hydrochloric Acid - chemistry Hydrogen Peroxide - chemistry Hydrogen-Ion Concentration Hydrolysis Impurity profile LC-MS/MS Magnetic Resonance Spectroscopy Oxidants - chemistry Oxidation-Reduction Photolysis Sodium Hydroxide - chemistry Spectrophotometry, Infrared Stability indicating method Tandem Mass Spectrometry Ultraviolet Rays |
title | Use of the hyphenated LC-MS/MS technique and NMR/IR spectroscopy for the identification of exemestane stress degradation products during the drug development |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T02%3A52%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20the%20hyphenated%20LC-MS/MS%20technique%20and%20NMR/IR%20spectroscopy%20for%20the%20identification%20of%20exemestane%20stress%20degradation%20products%20during%20the%20drug%20development&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Stolarczyk,%20El%C5%BCbieta%20U.&rft.date=2017-11-15&rft.volume=109&rft.spage=389&rft.epage=401&rft.pages=389-401&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2017.08.033&rft_dat=%3Cproquest_cross%3E1935385074%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1935385074&rft_id=info:pmid/28865686&rft_els_id=S0928098717304906&rfr_iscdi=true |